Like its Senate counterpart last week, the Innovation Act comfortably passed out of committee yesterday after mark-up by the House Judiciary Committee. It did so, however, with notable concerns yet to be resolved. In separate statements the Biotechnology Industry Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Venture Capital Association (NVCA) all made plain their opposition to the amended bill. That means that neither bill has won the kind of broad industry support that is normally vital in moving legislation to a vote in both chambers of Congress.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

IAM is the only publication that places a business focus on intellectual property. Readers are given real insight into, and guidance on, managing intellectual property as a true business asset.

Marc Kaufman
Partner
Reed Smith LLP

Benefits

Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?